Artwork
iconShare
 
Manage episode 506738025 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

September 16, 2025 | With the rise of AI and automation, what is the core human skill in drug discovery that is and will be valuable in the future? Derek Lowe, director of Chemical Biology Therapeutics at Novartis and author of the In the Pipeline blog, discusses the impact of AI—and non-AI technologies—on the business of drug making. With host Christopher Bahl, cofounder and CEO of AI Proteins, their conversation covers the value of a PhD in the tech world today, the long-term impacts of knowledge creation in US leadership positions, how the industry can navigate a biotech winter, and more.

Links from this episode:
AI Proteins
Novartis
In the Pipeline

  continue reading

Chapters

1. Introduction to Derek Lowe (00:00:00)

2. Technologies Beyond AI in Drug Discovery (00:01:57)

3. Human Skills in Research's Future (00:06:28)

4. The Value of PhD in Biotech (00:20:57)

5. Funding Cuts to Scientific Research (00:31:30)

6. Boston's Biotech Ecosystem (00:35:13)

7. Navigating the Biotech Winter (00:38:53)

8. AlphaFold Clones and Patent Challenges (00:42:13)

81 episodes